SCHEMBL9119174

SCHEMBL9119174

CCN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn4c3c2OC[C@@H]4C)CC1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.81
ALDH1A1 P00352 6/20 0.81
HPGD P15428 5/20 0.81
HSD17B10 Q99714 3/20 0.81
ALB P02768 1/20 0.81
HRH3 Q9Y5N1 1/20 0.81
TUBB4A P04350 5/20 0.80
TUBB P07437 5/20 0.80
TUBA3C P0DPH7 5/20 0.80
TUBA1B P68363 5/20 0.80
TUBA4A P68366 5/20 0.80
TUBB4B P68371 5/20 0.80
TUBB3 Q13509 5/20 0.80
TUBB2A Q13885 5/20 0.80
TUBB8 Q3ZCM7 5/20 0.80
TUBA3E Q6PEY2 5/20 0.80
TUBA1A Q71U36 5/20 0.80
TUBA1C Q9BQE3 5/20 0.80
TUBB6 Q9BUF5 5/20 0.80
TUBB2B Q9BVA1 5/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9194920 1.00 KDM4E (0.81) KDM4EALDH1A1HPGDHSD17B10ALB
Hydrochloric Acid SCHEMBL10476885 0.98 KDM4E (0.80) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL9636898 0.93 KDM4E (0.81) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL10437299 0.93 KDM4E (0.81) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL9235831 0.92 KDM4E (0.80) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL10437287 0.91 KDM4E (0.79) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL11079240 0.91 KDM4E (0.81) KDM4EALDH1A1HPGDHSD17B10ALB
Levofloxacin Anhydrous SCHEMBL27735741 0.91 KDM4E (0.94) KDM4EALDH1A1HPGDHSD17B10ALB
Levofloxacin Anhydrous SCHEMBL28456042 0.90 KDM4E (0.93) KDM4EALDH1A1HPGDHSD17B10ALB
Ofloxacin SCHEMBL28252624 0.90 KDM4E (0.93) KDM4EALDH1A1HPGDHSD17B10ALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0354453-B1 Antimicrobial agent for animals DAIICHI SEIYAKU CO (JP) 1995-01-25 EP claimed
EP-0206283-B1 OPTICALLY ACTIVE PYRIDOBENZOXAZINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1993-01-27 EP claimed
US-5175160-A Nontoxic, broad spectrum DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1992-12-29 US claimed
US-5053407-A OPTICALLY ACTIVE PYRIDOBENZOXAZINE DERIVATIVES AND ANTI-MICROBIAL USE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1991-10-01 US claimed
EP-0206283-A2 Optically active pyridobenzoxazine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1986-12-30 EP claimed
US-11746116-B2 Antibiotic resistance breakers KING'S COLLEGE LONDON (GB) 2023-09-05 US disclosed
EP-0354453-B1 Antimicrobial agent for animals DAIICHI SEIYAKU CO (JP) 1995-01-25 EP disclosed
US-5175160-A Nontoxic, broad spectrum DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1992-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11746116-B2 Antibiotic resistance breakers ABCC1, ARL1, AKR1C3 KDM4E 3599/4885ALDH1A1 481/4885HPGD 3875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.